^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    AmoyDx® PIK3CA Five Mutations Detection Kit

    Company:
    Amoy Diagnostics
    Type:
    CE Marked
    Related tests:
    Evidence Level:
    Resistant: C3 – Early Trials

    [PIK3CA mutation-Colorectal Cancer-]

    Source:
    Cell Death Dis
    Test:

    AmoyDx® PIK3CA Five Mutations Detection Kit

    Title:
    PIK3CA mutations confer resistance to first-line chemotherapy in colorectal cancer
    Excerpt:
    All patients involved in this study received first-line chemotherapy regimens, which were FOLFOX and XELOX in 420 cases...The patients resistant to first-line chemotherapy showed higher percentage of PIK3CA mutation than those effective...elevated disease-progression rate in the patients with PIK3CA mutant tumors than whole cohort (24.38%, p = 0.003, Fig. 1b), which indicated a poor chemotherapy response in PIK3CA mutant CRC.
    DOI:
    10.1038/s41419-018-0776-6
    Evidence Level:
    Resistant: C3 – Early Trials

    [PIK3CA mutation-Colorectal Cancer-]

    Source:
    Cell Death Dis
    Test:

    AmoyDx® PIK3CA Five Mutations Detection Kit

    Title:
    PIK3CA mutations confer resistance to first-line chemotherapy in colorectal cancer
    Excerpt:
    All patients involved in this study received first-line chemotherapy regimens, which were FOLFOX and XELOX in 420 cases...The patients resistant to first-line chemotherapy showed higher percentage of PIK3CA mutation than those effective...elevated disease-progression rate in the patients with PIK3CA mutant tumors than whole cohort (24.38%, p = 0.003, Fig. 1b), which indicated a poor chemotherapy response in PIK3CA mutant CRC.
    DOI:
    10.1038/s41419-018-0776-6